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Abbreviations: 
ACE, Angiotensin converting enzyme 
ADME, Absorption, Distribution, Metabolism, Excretion 
API, Active Pharmacological Product 
ARB, Angiotensin II receptor blocker 
ATMP, Advanced Therapy Medicinal Products 
AUC, Area under the curve 
CAD, Coronary artery disease 
CRISPR, Clustered regularly interspaced short palindromic repeats 
DCM, Dilated cardiomyopathy 
EMA, European Medicines Agency 
FDA, Food and Drug Administration 
GLP, Good laboratory practice 
GMP, Good manufacturing practice 
HF, Heart failure 
HFpEF, Heart failure with preserved ejection fraction 
INDs, Investigational new drugs 
LAD, Left anterior descending 
LV, Left ventricle 
MA, Market authorization 
MI, Myocardial infarction 
NOAEL, No observed adverse effect level 
PCI, percutaneous coronary intervention 
PD, Pharmacodynamic 
PDE, Phosphodiesterase 
PES, Programmed electrical stimulation 
POC, Proof of concept 
SOC, Standard of care 
TAC, Transverse aortic constriction 
  




Heart failure (HF) remains a major cause of death and hospitalization worldwide. Despite 
medical advances, the prognosis of HF remains poor and new therapeutic approaches are 
urgently needed. The development of new therapies for HF is hindered by inappropriate or 
incomplete preclinical studies. In these guidelines, we present a number of recommendations 
to enhance similarity between HF animal models and the human condition in order to reduce 
the chances of failure in subsequent clinical trials. We propose different approaches to 
address safety as well as efficacy of new therapeutic products. We also propose that good 
practice rules are followed from the outset so that the chances of eventual approval by 
regulatory agencies increase. We hope that these guidelines will help improve the translation 
of results from animal models to humans and thereby contribute to more successful clinical 
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1. Introduction 
Heart failure (HF) – and its most common co-morbidities, coronary artery disease 
(CAD) and hypertension – is a major cause of death and hospitalization worldwide. HF 
represents a major concern for medicine and society in general, both from a public health and 
a financial perspective. Its prevalence is very high, reaching 10% among the elderly and is 
expected to increase by 46% over the next two decades in the US [1]. Current treatment for 
HF patients, especially those with systolic dysfunction, is mainly palliative, and involves 
diuresis, chronic administration of beta-blockers, antagonists of angiotensin converting 
enzyme (ACE), and aldosterone and neprilysin inhibitors [2,3]. In addition, patients’ 
adherence to treatment is often limited [4] and some become refractory to medication [5]. 
Patients with ventricular dyssynchrony can benefit from cardiac resynchronization therapy 
(CRT), with or without an implantable cardioverter defibrillator [2,6]. Alternative solutions 
for some end-stage HF patients include left ventricular (LV) assist devices or transplantation 
[2,7]. HF patients with diastolic dysfunction and preserved ejection fraction (HFpEF) 
represent almost half of all HF patients [8]; however, there are no standard diagnostic criteria 
or treatments for this condition, and HFpEF represents a major unmet medical need [9]. 
Overall, and despite advances in medical management, the prognosis of HF remains poor, 
and the number of deaths associated with this condition has not decreased over the last 15 
years [1]. The need for investigational new drugs (INDs) and other therapies that might 
reverse or prevent the development of heart failure is therefore urgent.  
 
2. Purpose of Translational Experiments 
The main objective of translational preclinical studies is to establish the safety and 
efficacy of a treatment in order to translate results from basic science into therapeutic 
advances for humans. However, in numerous instances therapies with efficacy in preclinical 
models have failed when applied to human clinical trials [10,11]. In the field of heart failure 
alone, many examples of translation failure can be cited, including cytokine inhibitors, 
endothelin antagonists, and vasopeptide blockers. This is a serious shortcoming that has 
substantially diminished interest within the pharmaceutical industry regarding insights 
gleaned from animal models. Worse, novel therapies for patients with heart disease are 
lacking. Undoubtedly, the explanations underlying these failings are multifactorial. However, 
we believe that in some cases the preclinical studies were suboptimal and/or biased and hence 
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premature to invoke large, multicenter, randomized clinical trials in humans with their 
tremendous costs. 
Examination of those prior trials can be instructive by revealing several reasons that 
likely contribute to the failure of effective translation [12]. In some cases, strategies tested in 
preclinical models did not manifest robust cardioprotective benefit. Many were not verified in 
multiple independent labs. Often, the tested agents were not administered at a clinically 
relevant point in time, i.e., after injury has occurred; rather, animals were pre-treated with 
drug before injury, a situation with little clinical relevance. Many observations made in mice 
were not tested in other species, including large animals. In some cases, protocols required of 
a rigorous clinical trial were not employed [12]. Furthermore, some models – especially for 
HFpEF – failed to provide evidence of HF (i.e., pulmonary edema, congestion) [13]. In these 
guidelines, we provide a set of recommendations for researchers carrying out translational 
experiments with the aim of developing therapeutic agents with greater prospects for success 
in humans. Translational experiments must accomplish some general objectives [14] as listed 
below (Table 1): 
Efficacy. Establishing a causal relationship between treatment exposure and a 
pharmacodynamics (PD) or salutary effect is an obvious major aim of preclinical 
experiments. Testing for proof of concept (POC) would, by definition, be performed in 
simulated HF, recognizing that animal models do not necessarily recapitulate all the features 
of the human syndrome, including its usual co-morbidities. 
Safety. While assessing efficacy can be more dramatic and gratifying, recognizing the toxicity 
of a new treatment is at least as important as demonstrating efficacy. This is a main cause of 
clinical trial failures and represents a major focus of regulatory agencies. As discussed below, 
the safety of cardiac drugs can critically depend on co-morbidities, especially background 
structural heart disease [15]. 
Validity. Recognizing that all models have limitations, choosing a HF animal model that 
mimics the human condition as closely as possible, with its common patient features and 
usual comorbidities (e.g., CAD and hypertension), is essential for the generalization of 
treatment effects to humans (construct validity). Limitations of construct validity also include 
the use of treatments, delivery routes and analytical methods that do not replicate the clinical 
setting [14]. 
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Standardization. The lack of standardized protocols in translational studies is a major 
obstacle to the proper comparison of preclinical results. Standardization will allow results to 
be compared and reproduced by other researchers. 
Proof of concept preclinical studies. It should be recognized that experiments carried out in 
experimental HF to provide POC for an investigated therapy are formally different from 
preclinical safety studies which require a more comprehensive approach and must be 
performed under good laboratory practice (GLP) conditions. Neither the US FDA nor the 
European Medicines Agency require that POC studies adhere to GLP requirements, but they 
look as closely for any evidence of toxicity in the disease models as they do for salutary 
activity. To avoid undue repetitions of tests, it may be advisable to carry out the POC 
experiments under a GLP environment if it can be reasonably anticipated that, if positive, 
their results will contribute to the Marketing Authorization (MA) dossier. 
 
3. Translational Animal Models of Heart Failure 
Translational successes in HF are uncommon. Multiple factors are involved in this 
disappointing outcome, including limitations of many preclinical animal models and/or lack 
of appropriate use of these models. Much emphasis over the last two decades has been placed 
on genetically-engineered mouse models, which have seemed to fall short on their promise to 
elucidate true targets for potential HF treatment. Positive results in mouse models should be 
the starting point of further investigation and not the reason for bold claims of future 
translational promise. Instead, small animal studies should lead to large animal pre-clinical 
studies in order to directly test the safety and efficacy of a treatment. 
 
3.1 Small Animal Models 
Despite the aforementioned limitations, small rodent models of cardiac injury and HF 
have been extensively and increasingly used over the last two decades to elucidate the 
pathologic responses to chronic ischemia and/or pressure overload stress. Their use has 
advanced our knowledge of adaptive and maladaptive remodeling, and in the process has 
unveiled the molecular mechanisms underlying these responses as rational drug targets [16]. 
A recent statement paper extensively described some of the models used in HF research [17]. 
Herein, we do not aim to recapitulate the methodological details of creating these models, but 
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rather to focus on mice and rats as translational models to study novel potential therapeutic 
strategies that can ultimately lead to first-in-man studies. 
The most commonly used mouse model of HF is transverse aortic constriction (TAC), 
originally developed to study compensated left ventricular (LV) hypertrophy in response to 
sustained after-load [18]. Varying degrees of delayed maladaptive cardiac remodeling, LV 
hypertrophy, LV dysfunction, and HF occur in this model depending on the degree of aortic 
narrowing and consequent hypertrophic stress [17]. This model has revealed several 
molecular targets that delay post-TAC progression of HF [19], although the overall clinical 
relevance of these targets remains speculative. 
More recently, as surgical methods have improved, myocardial ischemia models in 
mice have been used, including both myocardial infarction (MI) via permanent occlusion of 
the left anterior descending (LAD) coronary artery and ischemia/reperfusion (I/R) injury 
through temporary ligation of the LAD artery [20]. Although the I/R injury model is best 
used to probe for acute cardioprotection, the post-MI HF that develops can be a target to test 
strategies to prevent or reverse LV dysfunction. Again, these models have been used to 
identify myocardial biochemical lesions in HF, but only a handful have been further tested as 
potential targets in large animal models [21]. Genetic mouse models of cardiomyopathy have 
also been used to test POC for a particular molecular pharmacological approach to HF [22]. 
Rat models of pressure overload and MI are also extensively used either for gene 
therapy approaches [23] or for testing small molecules [24] for halting or even reversing HF. 
Because such models have been used so often, much about the properties and the metabolism 
of small molecules in this species is already known. Accordingly, these models may be 
preferred over mouse genetic models, which are more costly and not as amenable to 
hemodynamic monitoring. In some respects (discussed below), rats do not offer much more 
in terms of translational significance but can add significant benefit in situations where 
known small molecules are tested for re-purposing as cardiovascular agents, especially when 
the rat pharmacokinetics is already known. The utility of the rat for modeling the chronic 
cardiac response to severe MI and for forecasting therapeutic effects of ACE-inhibitors is 
well established. For instance, this model reproduces the effect of enalapril and captopril in 
humans with HF, namely restoring filling pressures and contractility [25,26], attenuating the 
progressive LV enlargement and dysfunction [27,28], and prolonging survival [27,29,30]. 
Rabbits with experimental aortic insufficiency (AI) have also been used to model 
chronic LV volume overload and eventual LV decompensation [17]. Surgery in rabbits is 
relatively uncomplicated, and they are amenable to invasive hemodynamic and serial 
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prospective echocardiographic monitoring. The model forecasts utility of vasodilators in AI 
and also provides echocardiographic markers of LV decompensation that are useful for 
timing drug intervention or replacement of the valve [31].  
 
3.2 Limitations of Small Animal Models and Recommendations 
Small animal models of HF or cardiac stress, especially genetically engineered mouse 
models, have elucidated the molecular pathways involved in the responses to such stress as 
targets for drug intervention. However, there are several limitations beyond uncertainty of 
translational testing in larger, possibly more relevant and easier to monitor, pre-clinical 
models. One limitation is that the mouse cardiovascular system is not necessarily pertinent to 
human physiology. The rapid heart rate (300-600 bpm), small size, and atypical handling of 
calcium and other ion currents in the rodent heart can limit extrapolating of any findings to 
larger animals and to humans. Thus, for targets involving calcium handling, one must be 
aware of this limitation and rely more on non-rodent models in which calcium is handled in a 
human-like fashion (e.g., rabbits and dogs) [32]. Another limitation of post-TAC, post-MI 
and genetic rodent models is that rodents bred for laboratory use are genetically 
homogeneous, if not virtually identical. This can limit successful translation, because human 
patients are genetically diverse. Accordingly, any result of a treatment or genetic 
manipulation in a mouse model needs to be robust in terms of HF modulation and 
reproducibility, because reliable large animal models are more genetically diverse. Although 
larger animal models may offer advantages in terms of human relevance, their therapeutic 
robustness and reproducibility may be more difficult to achieve because physiological 
responses of large animals are likely to vary more.  
Overall, there is certainly a place for small animal models in the translational 
paradigm to elucidate and evaluate novel HF therapies, but the preliminary results in these 
animals must be corroborated in larger animals that provide additional efficacy and safety 
evidence necessary to extrapolate to humans. 
 
3.3 Large Animal Models 
As mentioned above, results in large animal models of HF are important, and in some 
cases critical, for a more informed prediction of a treatment’s effect because of the 
opportunity for robust testing in a more genetically diverse mammal that is more similar to 
humans, and in whom co-morbidities might be more readily introduced. Sheep, pigs, and 
dogs all have been used for modeling HF [17]. In these models, HF can be induced by 
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tachycardia (i.e., pacing) [33,34], ischemia provoked by either coronary artery occlusion 
[35,36] or micro-embolization [37], or volume overload [38,39]. They differ in their 
pathological characteristics and offer distinct advantages and disadvantages for testing 
therapies. For instance, the pacing model is very reproducible in its phenotype, but sustaining 
tachycardia with full instrumentation restricts utility to short-term studies of potential 
therapies [17,33]. Models of ischemic HF in large animals probably offer the best simulation 
of human disease, although robust and reproducible phenotypes may be difficult to obtain and 
some species, such as the pig, are prone to arrhythmias [17,40]. In any case, these large 
animal studies are the logical next step in testing a small molecule or biological material that 
might portend salutary or adverse activity, once initial evidence has been obtained in small 
animals. Importantly, when studies proceed to the large animal stage, it is crucial to use a 
study design that has the most clinical relevance (summarized in Table 2). We point to one 
example of a recent, large-animal study by one of us (JAH), which employed rigorous 
methodology mimicking those typical of a clinical trial: pre-specified endpoints and power 
calculations, randomization, and strict blinding of personnel [41].  
 
3.4 Other considerations 
Comorbidities. Patients with HF usually present with CAD and/or hypertension, often in the 
context of arrhythmias, structural heart disease from prior MI, angina, diabetes, sleep apnea, 
or anemia, all of which can affect therapeutic outcome [1,2]. Therefore, it is prudent to take 
into account the usual and possible co-morbidities when designing a preclinical experiment, 
in trying to replicate the context of the target patient population. A prominent example of this 
need are the excess arrhythmias and sudden death caused by certain class 1c antiarrhythymic 
agents (e.g. encainide, flecainide) used in patients with prior MI and depressed LV function 
in the CAST trial [15]. This arrhythmogenic activity of flecainide was forecast by its 
behavior in a model of acute focal myocardial ischemia [42]. 
Validation in other species and strains. The results obtained in one species or even in one 
strain of animals are often difficult to reproduce in a similar model in another species or 
strain. For instance, p38 inhibition has a cardioprotective effect in the infarcted mouse heart, 
but not in the pig [43]. Similarly, survival rate and extent of heart remodeling and LV 
dysfunction in the mouse after myocardial infarction are strain-dependent [44]. These reports 
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reinforce the need to validate results in a second animal model in which the PD activity of the 
IND is expressed, and calibrated with positive controls.  
Induction of disease. Human disease is induced in animal models in different ways that may 
significantly affect the outcome of the tested treatment. Induction of dilated cardiomyopathy 
(DCM) through genetic methods (e.g., knockout or transgenic overexpression) may elicit a 
different response from administration of cardiotoxic agents, pressure overload, myocardial 
infarction, or other interventions that induce DCM. 
Need for more than one model. Efficacy should be documented in more than one preclinical 
model. All models have limitations that may obfuscate the results of an experiment and may 
lead to optimistic over-interpretations of a treatment’s potential [17]. 
Reproducibility. Reproducibility should be documented across several labs working 
independently. Environmental factors, such as the generally accepted microorganisms found 
in any animal facility, may confound results. Similarly, small differences in methodology, 
reagents, infrastructure, or the researcher’s technical skill have resulted in different outcomes 
for the same intervention [45]. 
Systems biology as a tool to establish differences between animal models and human disease. 
All animal models have intrinsic features and limitations. Perhaps systems biology will 
emerge as an effective means of deciphering these complexities. The term “translational 
systems medicine” has been coined for strategies that involve the use of basic and clinical 
approaches combined with high-throughput technologies in genomics, proteomics, 
nanofluidics, single-cell analysis, and computational strategies [46]. This holistic approach to 
science in the context of a cross-disciplinary environment may provide the necessary insights 
to decipher which effects are common to humans and animals [46]. Although this promise 
has not materialized yet, it will likely lead to even better animal models. 
 
4. Effective Experimental Design for Pre-Clinical, Translational HF Studies 
4.1 Comparison to standard of care 
Initial POC studies usually aim to demonstrate efficacy of a new therapy in treated 
versus untreated animals. Once this has been achieved, tested interventions should be 
compared against current standard of care (SOC). Sometimes what constitutes SOC can be 
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challenging to define, especially in non-human studies, and it might be uncertain whether the 
relative effectiveness ranking is the same in animals and humans. It should be transparent to 
outsiders what the comparator was in each experiment and why it was selected. The 
components of the comparator interventions need to be carefully described so that the 
experiments can be confirmed by independent investigators. To illustrate, recent studies have 
compared experimental therapies to -adrenergic receptor blockade and included -blocker 
arms alone versus together with the therapy [23,47]. ACE inhibitors, angiotensin receptor 
blockers (ARBs), and diuretics that are approved for HF can be added to the study design to 
test not only for positive or negative drug interactions, but also to further calibrate the model. 
Calibration with drugs approved for HF will guide the future choice of a model. Moreover, 
testing for safety in a model where targeted PD activity is also evident provides a 
“veterinary” therapeutic safety multiple to be compared with that of a SOC agent. Unless 
there are conditions where HF SOC drugs are not used, adding such cohorts to a study design 
is important, because at least initially, all advanced clinical trials will be conducted to 
demonstrate at least non-inferiority to the SOC cohort(s) in terms of efficacy and/or 
tolerability. This could be an issue in large animal studies as it increases the number of 
animals and space required, together with the cost of the study. Certainly, studies using 
mouse and rat models are more amenable to adding these SOC cohorts and should precede 
any large animal studies. To show that a new treatment strategy is more effective than -
blockers, for example, it is necessary to test it in small animals before using a large animal 
model to justify the increased cost and time commitment in the attempted translation.  
 
4.2 Age and Sex 
Preclinical models should try to approximate the human disease context as closely as 
possible. In this regard, age and sex may be important modifiers. There is little empirical 
evidence about how interventions in animal models perform when tested in different sexes or 
in animals of different age, but often animals are chosen with only one sex or with a peculiar, 
if not irrelevant, age range, without proper justification [48]. These issues of generalizability 
based on basic demographic characteristics in the clinical trials can, of course, restrict 
labeling at time of approval.  
 
4.3 Negative Controls 
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Careful consideration should be given to the choice of controls. Depending on the 
intervention, they may need to involve sham procedures, which may give very different 
results from no treatment intervention at all. For cell experiments, controls may include 
various types of cells to increase potential insights into safety aspects.  
 
4.3 Randomization & Blinding 
In testing therapeutic or preventive interventions in preclinical (or clinical) research, 
there is no justification for not using a rigorous randomized design. Lack of randomization 
can allow biases that are very difficult if not impossible to control post-hoc by analytical 
manipulations. Moreover, for all preclinical studies, it is essential to ensure that the 
investigators are blinded to the allocation of interventions to combat potentially powerful 
allegiance biases. If blinding of the investigators is impossible (e.g., due to easily 
recognizable secondary changes being introduced into the experimental system by one of the 
interventions or comparators), this should be clearly described along with the other measures 
taken to minimize potential subjective bias in reading the results. Bias due to lack of blinding 
is likely to be more prominent for measurements that entail some subjective assessments. 
 
4.4 Timing & Dose-response 
Timing and dose-response assessments should also try to anticipate the eventual 
extension of successful interventions to human clinical trials and human use. Differences in 
half-life and perhaps in active metabolites have to be considered when trying to establish or 
extrapolate exposure-response relationships.  
 
4.5 Define Inclusion/Exclusion Criteria 
Inclusion/exclusion criteria for relevant variables (e.g., infarct size) should be 
carefully reported. For example, it should be clarified whether the choice is intended to create 
a sample that is more uniform for minimizing experimental variability or more widely 
representative of different conditions and settings.  
 
4.6 Analysis Time Points 
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It is also important to pre-specify time points at which results will be analyzed, as 
well as to justify their choice based on pathophysiology considerations, previous studies, or 
other evidence. Analyses of multiple time points should have an explicit analysis plan to 
avoid multiplicity problems from non-corrected multiple views at the data. Analyses should 
accommodate the baseline measurements and properly handle missing data to avoid some 
popular but erroneous techniques (such as last observation carried forward). 
 
5. Housing, Treatments and Interventions 
5.1 Animal Housing and Confounding Physiological Variables 
Many factors should be considered in planning for both adequate and appropriate 
physical and social environments, including housing, space and availability or suitability of 
enrichments. Several guidelines are available on the subject, in publications [49] and websites 
(www.aaalac.com, iacuc.utk.edu). Furthermore, Good Laboratory Practices (see below) 
should be followed given that the results will be submitted to regulatory agencies such as the 
US FDA and EU EMA, which also issue specific guidelines periodically [50]. 
Temperature, humidity, lighting, noise, and concentrations of gases and particulates 
can affect metabolism, physiology and susceptibility to disease. Body temperature of the 
animals must be maintained in their physiological range (rodents, 38-39 ºC; rabbits, 38-39.6 
ºC; pigs, 38.3-39 ºC). This is especially delicate in rodents because they easily lose body 
temperature (animals may die under 35º C). Animals suffering heart failure will harbor lower 
body temperature in their extremities, so heating pads or nest material should be provided to 
keep them comfortable.  
 Exposure to sound louder than 85 dB or non-homogenous animal handling can affect 
blood pressure in small animals like rats as well as in larger animals such as non-human 
primates [51,52]. Thus, changes in blood pressure might not directly reflect HF but rather 
environmental factors. Assessing blood pressure in conscious animals can be challenging if 
they are not acclimated. Rodents will experience tachycardia when under threat or 
manipulation stress. Therefore, it is important to perform repeated training and handling 
before starting the experimental procedure. This is crucial if blood pressure is one of the 
parameters to study. 
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Studies of circadian biology for cardiovascular disease indicate that diurnal rhythms 
(24 hour day-night cycle) should also be taken into consideration, as the choice of the animal 
— nocturnal (rodents) vs. diurnal (larger animals) — might affect the disease model and the 
preferred time of the therapeutic intervention [53,54]. The major importance of diet has 
clearly been illustrated in, for example, the high-cholesterol diet rabbit model widely used for 
experimental atherosclerosis. Such a diet combined with arterial wall injury produced 
valuable results on plaque rupture in early models of atheroma inflammation [55-57], 
inflammation-associated atherosclerosis [58], and even in models of vulnerable 
atherosclerotic plaque [55]. Veterinary advice also should be available to ensure the best diet 
to maintain animals in optimal health with all nutrient requirements provided. 
 
5.2 Anesthesia, Analgesia and Potentially Confounding Treatments 
Careful administration of anesthetic and analgesic drugs provides an appropriate level 
of hypnosis, muscle relaxation, and analgesia while minimally affecting autonomic function 
and the cardiovascular system. These drugs must suit the particular needs of the animals and 
the characteristics of the experimental procedure employed. Opioids should be administered 
for invasive and painful procedures, such as a thoracotomy to place an aortic band in dogs or 
a transverse aortic constriction in mice. For example, fentanyl can be used for severe pain as 
it provides potent analgesia, but only in short duration; buprenorphine can be administered 
for moderate pain and for postoperative care as it provides a good level of analgesia with long 
duration. Inadequate analgesia during and after surgery can lead to undesirable 
pathophysiologic responses, such as tachycardia, elevated blood pressure, or high catabolic 
demand, and will thus increase post-operative mortality and morbidity. 
Anesthesia can be provided either with inhaled or intravenous agents. In general, 
administration of low doses of the anesthetic drug has lower risks and produces less 
cardiovascular depression. A combination of anesthetic and analgesic drugs (balanced 
anesthesia) to reduce the amount of anesthetic agents will increase the safety of the 
procedure. In particular, the use of sevoflurane instead of isoflurane or halothane is 
recommended due to the adverse effects of the latter, especially in pigs, which are more 
susceptible to developing malignant hyperthermia and cardiotoxicity when used with β-
blockers. When using anesthesia during the experimental period or sample isolation (blood 
sampling, control echocardiography, etc.), animals may show different degrees of 
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hypotension, bradycardia, arrhythmias, hypoxia, and an increase in diuresis that could mask 
heart failure symptoms.  
Some anesthetic drugs, including propofol and halogenated volatile anesthetic agents, 
manifest pre- and post-conditioning cardioprotective properties via different mechanisms of 
action. Therefore, the choice of the anesthetic agent and the protocol of administration should 
be carefully considered when evaluating the therapeutic potential of a given compound. No 
changes in anesthesia should be introduced in the middle of an experimental protocol so as to 
avoid unknown confounding effects on the experimental model and experimental results. 
 
5.3 Treatment Delivery 
Delivery of the studied therapeutic product in experimental animals should follow the 
same pattern as in humans, but doses must be adjusted to the size of the animals [59]. 
Intramuscular administration is an easy delivery route, requiring only the proper handling of 
the animal, but it is probably the least frequent in humans. Oral administration in small 
animals can be performed by oral gavage if the drug can be dissolved. If not, it can be given 
mixed with the chow. In large animals, drugs can be mixed (if powdered or crushed) with the 
chow or administered with a special pill-gun as a whole pill. If given with the chow, it may 
be convenient to confirm the presence of the drug or its metabolites in the blood to ensure 
delivery. Chemical stability of the studied drugs must be known before deciding the route of 
administration. Administration of biological products, such as cells or viral particles, should 
follow the same route that would be used in humans (e.g., through PCI). Treatment delivery 
can be confirmed in live animals or after necropsy (see section 6.4 below). Animal models 
are also useful to guide the development of new delivery methods [60].  
All treatment administrations that require the intervention of the investigator are able 
to induce stress in animals. As death can occur in diseased and weak animals, this is an 




Once the efficacy of a new treatment has been established against untreated control 
animals in POC experiments, additional investigations should be carried out in the context of 
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clinical SOC. New treatments should be tested in the presence of adequate co-medications. 
This is particularly relevant to biological products, because initial clinical trials in humans 
will likely be carried out in the presence of SOC drugs that might mask the beneficial effect 
of the tested product. Therefore co-treatment with standard HF drugs (-blocker, ACE 
inhibitors, etc.) should try to mimic the scenario of a future clinical trial. 
 
6. Endpoints and Analysis 
Given the large number of end points that can be selected and the even larger array of 
options of how to measure them, the protocol in animal studies should pre-specify explicitly 
the end points of interest, how they are to be measured, and how they are to be analyzed 
(Table 3). 
 
6.1 Cardiac Function and Ventricular Remodeling 
Cardiac function can be measured invasively or non-invasively. Invasive 
measurements provide detailed information on pressure-related parameters, whereas non-
invasive measurements are capable of evaluating structural parameters. Echocardiography 
and magnetic resonance imaging (MRI) are the most frequently used non-invasive modalities 
for evaluation of cardiac function. Both modalities provide similar systolic function 
parameters, such as left ventricular ejection fraction and stroke volume, which are also 
widely accepted indices in clinical care [61]. While echocardiography offers wide availability 
and lower costs, MRI has superior spatial resolution that provides more accurate volumetric 
assessments and less variability [62]. When using echocardiography, the use of three-
dimensional echocardiography is recommended for assessing ejection fraction to reduce 
geometric assumptions made by two-dimensional and M-mode echocardiography and their 
less reliable fractional shortening index of LV function [63,64]. 
Recent advances enable assessment of myocardial deformation with both MRI and 
echocardiography, offering opportunities to assess regional wall motion [65]. These 
approaches provide insight into the mechanical function of the myocardium in myocardial 
infarction, valve disease, diastolic dysfunction and ventricular dyssynchrony for patients or 
animals undergoing CRT [66]. Myocardial deformation imaging can detect subclinical 
ventricular dysfunction and allows early detection of cardiotoxicity [67]. Invasive metrics of 
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systolic function include left ventricular end-systolic pressure, maximal first derivative of LV 
pressure (dP/dt max) obtained by a left ventricular manometer, and cardiac output by a Swan-
Ganz catheter. All of the above indices are known to be influenced by loading conditions, and 
several approaches are proposed to adjust for load status [68,69]. The pressure-volume loop 
relationship can be determined to accurately evaluate changes in intrinsic, i.e., load- 
independent, contractility. 
A frequently overlooked issue in the noninvasive assessment of cardiac size and 
performance is the effects of anesthesia. Rodents exposed to deep anesthesia become 
bradycardic, hypothermic, and hypercarbic owing to respiratory depression, each of which 
strongly affects cardiac function. Rodents analyzed by MRI are particularly susceptible, as 
the anesthesia required is deep and ventilator support is often not provided. It is critical that 
these changes be tracked and accounted for in the ongoing analyses. 
Assessment of diastolic function is better established by echocardiography for non-
invasive measurement with the use of Doppler-derived parameters, including tissue Doppler 
imaging. Many indices are available, including the ratio of early (E) to late (A) diastolic 
filling, E wave deceleration time, and mitral inflow propagation velocity [70]. Passive 
diastolic function can also be evaluated by end-diastolic pressure-volume loop relationships, 
although this is an invasive approach and usually requires subsequent euthanasia. Pressure-
derived indices have the advantage of higher temporal resolution for assessing the active 
diastolic function as represented by the time constant of relaxation (tau) and minimal first 
derivative of LV pressure (dP/dt min). 
Parameters that reflect functional impairment vary depending on the type of disease. 
Ejection fraction is more sensitive than dP/dt max in detecting MI-induced systolic 
dysfunction [69], but it is well maintained until the late stage of mitral regurgitation-induced 
HF [71]. Thus, any of the above modalities alone is insufficient to independently provide full 
information on cardiac function, and a combination or complementary approach is usually 
preferred. Multimodality assessment is recommended to comprehensively evaluate cardiac 
function. 
 
6.2 Tissue Remodeling, Fibrosis and Inflammation 
Tissue remodeling can be assessed by different histological and molecular 
approaches. Collagen deposition can be assessed as Masson’s trichrome or picrosirius red 
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staining. Picrosirius red also allows quantifying collagen crosslinking by using polarized 
light. Cardiac fibrosis can also be estimated with MRI. Late gadolinium enhancement allows 
visualization of the scar region [72], whereas diffuse fibrosis can be determined using the 
myocardial extracellular volume fraction (ECV) as an indicator of the connective tissue 
fraction [73]. Cardiomyocyte hypertrophy can be estimated by measuring cell cross-sectional 
area after staining with wheat germ agglutinin [74]. Myocardial expression of HF markers 
such as BNP, -skeletal, actin and, in some species, -myosin heavy chain can be determined 
by qRT-PCR or by Western blot [75,76]. Expression of inflammation and fibrosis-related 
markers can also be quantified in this manner [77]. Additionally, ELISA can be used to detect 
BNP, troponin, cytokines, and hormones in the blood [78]. The analysis of proteomic and 
transcriptomic profiles in the affected heart will provide further information on protein and 
gene modifications [79,80]. 
 
6.3 Cardiac Metabolism 
Myocardial viability and metabolic function can be assessed by non-invasive imaging [81]. 










FTHA) as radiotracers. Metabolic changes and mitochondrial activity can be determined by 
magnetic resonance spectroscopy (MRS), which allows non-invasive real-time quantification 
of pyruvate, phosphocreatine, ATP and inorganic phosphate [81,82]. Changes in metabolite 
concentration can also be determined biochemically although tissue phosphocreatine and 
ATP are unstable and are best determined by MRS. 
 
6.4 Confirmation of Treatment Delivery 
For some treatments, especially biologicals such as those used in cell or gene 
therapies, it is necessary to verify that the therapeutic agent has been effectively delivered to 
the targeted organ. The delivery of a viral vector can be confirmed by qPCR, and the 
expression of the therapeutic gene can be quantified by qRT-PCR or Western blot. The 
biodistribution and expression in organs other than the target organ or cell type should be 
analyzed by qRT-PCR and immunohistochemistry. The presence of transplanted cells can be 
visualized in the live animal by MRI (superparamagnetic iron oxide (SPIO) labeled cells) or 
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after necropsy by histological methods and confocal microscopy. Cell delivery and 
engraftment can be quantified by qPCR or Western blot using markers specific for the 
therapeutic cell population. 
 
6.5 Confirm Efficacy via More than One Measurement 
Efficacy should be measured by more than one index when possible. Imaging should 
be accompanied by target tissue analysis and tentatively by systemic biomarker changes, as 
discussed above, ideally in both small and large animal species as recommended above. 
 
6.6 Secondary Effects of Treatment on Other Organs 
Risk for any direct or indirect collateral pharmacodynamic activity can be tested in 
vitro and in vivo. The pharmaceutical industry and regulators both rely upon data from a 
battery of in vitro receptor and transporters binding assays in forecasting such activity. In 
intact animals, and in some animal disease models, circulating markers of organ function and 
histomorphology provide evidence of any acute safety pharmacology issues, organ 
dysfunction or tissue damage. A variety of methodologies and techniques can be used to test 
for unintended effects of a given intervention, including qPCR, biochemistry and histological 
analysis for direct or immunopathic lesions. Animal disease models may be needed to 
identify certain risks, such as the arrhythmic activity of class 1c antiarrhytmic agents and 
positive inotropes (see below). 
 
6.7 Survival 
Whenever possible, survival experiments should be prioritized to gain information on 
efficacy and safety. However, these follow-up studies are expensive and hence their utility 
must be clearly foreseen and accepted by granting agencies and pharmaceutical companies, 
especially in large animal studies. During the experimental procedure, all animals should 
follow the welfare protocol that assesses the end points. Animals that have successfully 
finished the experimental procedure plus follow up should be euthanized in order to obtain 
samples for the study. Animals that cannot be further studied should be euthanized following 
the ethical codes for animal research. 
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7. Phamacokinetics: Absorption, Distribution, Metabolism, Excretion (ADME) 
ADME parameters (i.e., AUC and Cmax) determine exposure in a healthy animal or a 
disease model and therefore the responses that are exposure-dependent in either scenario. 
Depending on whether there is subsequent hepatic or renal dysfunction associated with the 
HF, or if any co-morbidities or co-therapies were introduced into the model, the blood levels 
of liver metabolites and/or renally excreted drugs can be significantly affected. Blood and 
tissue levels may also change over time in a trial in simulated HF [83]. Actual AUC or Cmax 
exposures achieved in vivo at pharmacodynamic or POC vs. toxic dosages, rather than 
relative mg/kg or mg/m
2
 dosages, provide an index of inherent therapeutic safety, and the 
bases for forecasting “veterinary” or clinical safety risks as for selecting a prudent “first in 
man” starting dose.  
 
8. Statistics, Power Calculations 
Studies should be properly powered to detect meaningful effect sizes. Underpowered 
studies run the risk of increasing the problem of both false-negatives and, given the current 
research environment with selective reporting, false-positives [84]. Moreover, when detected, 
estimates of false positives or false negatives are likely to be inflated in underpowered 
studies, even for genuine effects [85]. 
 Besides proper sample size calculations, some other aspects of the statistical design 
are essential. Some have argued that the protocol and analysis plan should be pre-specified 
and ideally deposited in public before the study is performed and data are analyzed. This may 
remedy the need for data dredging (inappropriate data fishing) after the fact. Even in 
experimental, randomized studies, there is ample room for data dredging that can take place 
post-hoc, including changes in the eligibility criteria, changes in the time, types, and 
measures for assessment of outcomes, and changes in the analytical model adopted for 
handling missing data, covariates, or other study-specific caveats. When analyses have not 
been pre-specified, investigators should clarify that this is the case so that the statistical 
analysis can be seen as exploratory and requiring independent validation in subsequent 
studies.  
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9. Toxicity 
9.1 Cardiac Toxicity in Animal Models 
Mammalian hearts share many physiological, cell signaling, and energetic features. 
They also share vulnerability to direct cytotoxic, ischemic, and overload insults. For instance, 
they react similarly to these insults with anatomic, electrophysiological, and energetic 
“remodeling” during chronic overload or persistent atrial fibrillation [86]. This can render 
animal disease models not only suitable for POC testing but, in some cases, also for more 
reliable safety (toxicity) testing. The potential use of animal models for functional safety 
assessment is increasingly discussed as new therapeutic modalities and targets are being 
identified and developed, especially including those for HF [87]. Moreover, 
histomorphological or functional safety studies performed in a disease model can provide a 
“veterinary” safety multiple based on the dosage that provokes histologic lesions and/or or 
compromises cardiac function compared to a pharmacodynamic dosage. Animal models of 
cardiac disease have reliably forecast adverse effects on cardiac physiological function, 
especially on normal sinus rhythm (e.g., pro-arrhythmogenicity of certain inotropes and anti-
arrhythmic agents) [42,88]. Use of experimental models of acute MI, for example, confirmed 
the clinically observed detrimental effect of Class 1B and 1C anti-arrhythmic drugs in 
patients with acute MI vs. beneficial effect of beta-adrenoceptor blocking agents in that 
context [89-91]. 
 
9.2 Translational Toxicology Studies 
Conventional toxicology studies of an IND for HF usually monitor gross and 
microscopic tissue integrity in a healthy animal rather than in a genetic or surgical model of 
HF, mainly due to the possible confounding of background lesions and the cost and 
inconvenience of the latter. Besides histomorphology and gross pathology, safety endpoints 
should include mortality (with cause of death), clinical observations, body weight, physical 
examinations, food and water consumption, clinical pathology (blood and urine), and organ 
weight. When testing biologicals, such as stem/progenitor cells or viral vectors, additional 
analyses should investigate the possibility of tumor formation or activation of the immune 
response. Known toxicities for similar treatments already found in other organs or disease 
settings should also be tested, taking into account that toxicities may appear late after 
treatment. Therefore, potential detrimental effects should be tested at different time points. 
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 Conventional toxicity studies are not typically designed to capture cardiac 
performance, rhythm, contractility, and loading conditions. This is an important limitation of 
routine testing for cardiac toxicity because adverse functional cardiac side effects are 
perceived to be more frequent than morphological and biochemical lesions [92]. An adverse 
effect on function can be an extension, or an indirect consequence, of targeted PD activity or 
it can be off-target, but sometimes that distinction cannot be made. Some positive inotropic 
agents like milrinone and vesnarinone promote cardiac death in HF, most likely due to 
ventricular tachyarrhythmias [93]. Certain anti-arrhythmic agents and other drugs used in HF 
that prolong the QTc interval carry a risk of torsades de pointe arrhythmia [42,88]. A HF 
model best suited to capture this or other arrhythmia liability would ideally recapitulate the 
underlying structural disease, mechanical and neurohumoral factors, electrolyte 
abnormalities, ischemia, and co-therapies that make up the context of such toxicity. However, 
some factors may be more important than others. For example, as opposed to the intact dog, 
the chronic anesthetized AV-blocked dog is reported to be highly vulnerable (>70%) to the 
torsadogenic effect of multiple Class III anti-arrhythmic agents (e.g., dofetalide, almokalant, 
and ibutilide), likely as a result of anatomic and “electrical” ventricular remodeling during 
prolonged AV block [88,94,95]. Normal sinus rhythm and stroke volume can be 
compromised by focal or global disturbances in conduction of electrical impulses or in 
myocardial metabolism, which are manifested as disruptions in atrial or ventricular rhythm or 
contractility. Cardiac output may be normal in that context via the operation of compensatory 
mechanisms, such as electrical or chamber remodeling that may ultimately be deleterious. 
 When important behavioral toxicity is detected in a disease model used to provide 
POC, especially at exposures less than the no observed adverse effect limit (NOAEL) in 
conventional safety studies, such a scenario should be further assessed by a GLP study, as the 
starting dose in humans will rely on the new NOAEL. Indeed, the safety data may even 
forecast risk, if not contraindication, in certain patient populations. A prominent example is 
the capacity of flecainide to raise the defibrillation threshold for cardioversion of PES-
induced arrhythmia in dogs with recent myocardial infarction [96]. This is consistent with the 
label warning against the use of this and other Class 1C anti-arrhythmic agents in patients 
with recent myocardial infarction and ventricular arrhythmias. 
 
9.3 Limitations of Animal Models 
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Although mammals share the same basic molecular biological architecture for 
coordinated cardiac contraction and the mechanisms that control it, the PD activity and safety 
of any given cardiac treatment do not always translate across species. For instance, the 
vasodilator and positive inotrope milrinone, a cardiac and vascular PDE-III inhibitor with 
limited approval in HF, is not cardiotonic in the rat, though the rodent expresses the cardiac 
PDE-III enzyme as does the human [97]. However, it is arrhythmogenic in both the intact rat 
and in the congestive HF patient, where it promotes sudden death [98]. Another critical 
translation principle is that safety can be disease-state dependent. The tachy-
arrhythmogenicity of milrinone is not apparent in the intact dog even when it is given with an 
arrhythmogenic dosage of ouabain, but it causes ventricular fibrillation when focal ischemia 
is present [99,100]. Similarly, the Class 1c anti-arrhythmic agent flecainide is pro-arrhythmic, 
and essentially contraindicated, in cardiac patients when they have a history of myocardial 
infarction, but its use is not restricted if structural heart disease is absent [15]. Accordingly, 
FDA’s Division of Cardiovascular and Renal Products, for example, expects that cardiotonic 
and anti-arrhythmic INDs will be tested for any pro-arrhythmia in animal disease models, 
especially those with background structural heart disease - the context in which excess 
arrhythmic death was seen in the CAST trial [15]. These examples illustrate that expression 
of toxicological cardiac dysfunction and other cardiac pathology depend on the 
pathophysiological state of the heart. 
 
10. Regulatory Aspects  
The development and adoption of new therapies for cardiac patients is tightly 
regulated. Compliance with these rules during preclinical investigation is intended to 
facilitate their translation to the clinic. Two independent but complementary concepts have to 
be distinguished in the lifecycle management of a medicinal product. The first concept deals 
with the “relevant criteria” and the “technical requirements” that need to be satisfied and 
documented. These establish the quality via chemical/biological analysis (GMP quality 
control testing) and both the safety and efficacy profile per studies in animal models (see 
above) and in clinical trial. Pre-clinical safety trials in at least one rodent and non-rodent 
animal species with PD activity is mandated, in addition to tests on safety (functional) 
pharmacology, genotoxicity, reproductive toxicity, and oncogenicity. In patients, placebo-
controlled, randomized, double-blind trials are needed. 
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The second concept is known as “good practice” (GxP) rules, which are to be 
followed in the development and commercialization chain. The GxP rules have been 
developed in at least three important sectors of a medicinal product development. The GLP 
(for Good Laboratory Pratice), GMP (for Good Manufacturing Practice) and GCP (for Good 
Clinical Practice) rules are thus intended to be implemented deliberately for preclinical 
testing, for the production and quality control of any investigational or commercial product 
planned for a human use and for the conduct of the clinical trials, respectively. 
In the US, non-clinical in vitro, in vivo, and ex vivo studies of toxicity and safety 
pharmacology are implemented by the Code of Federal Regulations [101], whereas in the EU 
the non-clinical development program is implemented in annex I of Directive 2001/83 [102]. 
For both regions, the GLP mandate is intended to assure validity and reproducibility of 
results of such studies by requiring that all underlying procedures be defined, monitored, and 
documented. GLP ensures the generation of verifiable, quality data for the dossier to be 
submitted for MA (IND in the US, MA in the EU) consideration. However, GLP validation is 
not scientific validation, rather a set of rules and requirements to ensure that agreed 
procedures have been followed (in the U.S., per the general provisions of CFR, sub-part A, 
§58.3). Such requirements are waived for basic exploratory studies performed to predict 
efficacy or to identify physical or chemical properties of a test article. Importantly, neither 
GLP nor GMP is sufficient to verify the relevance of the tests or process performed under this 
“quality system”. The adequacy both of the manufacturing process or quality control strategy 
and of the non-clinical testing plan to achieve the legitimate expectation of quality and safety 
for a medicinal product, are primarily dependent on the design and execution of the 
development plan. 
 
10.1 Technical Requirements 
Marketing authorization of a medicinal product can only be issued after assessment 
and review of a “marketing authorization dossier” documenting the following “relevant 
criteria”: i) the quality profile of the product, which includes the characterization studies, the 
production/purification process, and the related quality control strategy; ii) the pharmaco-
toxicological data to establish the safety profile; and iii) the clinical data, to establish the 
clinical benefits and the adverse effect profile. Based on this composite, the valuation process 
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will derive a risk/benefit assessment for granting marketing authorization and writing the 
product literature for both prescribers and patients.  
 
10.2 Technical Criteria for Documenting the Quality Profile 
Quality aspects cover the characterization and establishment of production and 
purification processes, ensuring that any batch will be released in a consistent manner with 
the expected quality, purity, and biological activity. It is strongly recommended, especially 
for Advanced Therapy Medicinal Products (ATMPs), that a dialogue be initiated with the 
regulators from the very outset of any clinical program to ensure that bench-scale procedures 
can be successfully translated into an approvable protocol. 
Cell manufacturing. In the case of cell-based therapies, specific conditions apply. The origin 
of the cells, infectious disease screening, the collection, cell culture, expansion, 
cryopreservation/storage/thawing procedures, and transport conditions should be precisely 
documented. Specific data to be recorded also vary according to the origin of the cells. In the 
case of autologous cells, the potential risk that the manufacturing process may lead to 
propagation of a pathogenic agent initially present in the donor should be assessed. For 
allogeneic cells, an extensive screening for infectious diseases (HIV, hepatitis, CJD, etc.) 
should be completed. When using cell scaffolds, these will be evaluated as medical devices 
according to tissue engineering-specific requirements (e.g., composition, degradation profile, 
biocompatibility, description of the manufacturing process and characterization of its 
residuals, sterility, and toxicity). For the combination product, cells will have to be evaluated 
as any isolated cell product, but cell-material interactions will also have to be thoroughly 
assessed. 
Raw materials and other reagents. All materials and reagents, including those specific to 
cell-culture media, have to be qualified and certified before they enter the GMP-certified 
production plant. As such, the traceability of all ancillaries and documentation about origin, 
sterilization procedures, and quality controls for each batch are major requirements, 
particularly if there is a risk that some of these compounds may persist in the final product. 
These issues should be worked out from the outset as it is often challenging to collect the 
relevant information, which may be protected by intellectual property rights. Also, to 
anticipate what might likely become a mandatory requirement in the years to come, the 
avoidance of xenogeneic products, the use of fully defined chemical media and synthetic 
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surfaces, and the development of automated systems incorporated in closed bioreactors 
should all be strongly encouraged [103]. 
Drug substances and drug products. A robust in-process quality control system, as well as an 
end-product testing program, are needed to generate a consistent product that meets the 
criteria required for release of a given batch prior to its administration (be it for a clinical trial 
or for commercialization). The major criteria include viability, sterility, identity (detection of 
specific surface markers or functional assays), tumorigenicity and genomic stability, purity 
(through the minimization of undesirable non-cellular impurities and cell debris), and 
stability both throughout the process (particularly if an intermediate period of 
cryopreservation has been used) and under the proposed shipping conditions. An important 
feature of this quality control system is the reliance on robust, sensitive, and specific 
analytical tools. Another key challenging criterion is the demonstration of potency, i.e., 
evidence that the biological activity of the final product meets the intended mechanism of 
action and therefore the therapeutic effect. 
 
10.3 Technical Criteria for Documenting the Safety Profile in Non-clinical Developments 
The main objectives of non-clinical (preclinical) tests are to identify the 
pharmacology and toxicity of an investigational drug and to minimize the risk associated with 
it in the initial clinical trials. The rationale for the non-clinical tests as well as the choice of 
the animal model(s) should be discussed and justified. 
Statistical evaluation. Power calculations to estimate sample sizes, randomization, choice of 
appropriate controls, and blinding are strongly recommended (see above). 
Test articles. Although the formulation may vary, the Active Pharmacological Ingredient 
(API) tested in non-clinical experiments should be essentially identical to the product 
intended for use in humans, especially for the initial clinical studies. However, it is not 
unusual for the production/purification process of the API to be subsequently modified to 
improve product quality, consistency and robustness during the normal development course 
of a medicinal product, particularly for ATMPs. The potential implications of such changes 
for extrapolation of the animal findings to humans should be considered and fully justified, 
especially if the impurity or degradation profile differs from that of the batches used in the 
critical non-clinical trials. 
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10.4 Good Laboratory Practice (GLP) 
The basic objective of GLP is to assure that reliable data for forecasting safety of 
pharmaceutical products is collected [104]. GLP consists of a quality system that 
encompasses the organizational process and the conditions under which non-clinical safety 
studies are planned, performed, monitored, recorded, archived, and reported. GLP rules also 
allow a mutual acceptance of the results and outcome from non-clinical animal tests, avoiding 
repetition and unnecessary use of animals. The United States FDA accepts studies performed 
per OECD guidelines or as promulgated under 21CFR58. 
Human resources. The non-clinical study plan should include a clear management structure 
that identifies the study director, the product under investigation, and the specific purpose of 
the study. The team should ensure compliance with GLP guidelines, conduct audits on the 
facilities and processes, and ensure that the final report correctly reflects the raw data 
accumulated during the study. 
General considerations. Facilities should have enough space to conduct the study, including 
isolated rooms if necessary. Source, date and conditions of animal arrivals should be 
recorded. A period of quarantine needs to be respected before experiments can be started. The 
product under investigation will need clear identification of date of receipt, expiration date, 
storage conditions, and stability under these conditions, quantities received versus actually 
used in studies, batch number, and composition. All reagents must be clearly identified and 
fully traceable. 
Procedures. Written standard operating procedures (SOPs) should be available for the tested 
products, equipment, and reagents. Relevant information on animals (species, strain, weight, 
age, sex, and source of supply) and product administration (route, dose, and frequency) 
should be precisely reported. As for a clinical trial, the experimental design, end points, and 
methods should be recorded and included in the final report. All data generated during the 
study should be recorded accurately, signed, and archived for the period specified by the 
appropriate authorities. A detailed report should be issued at the completion of the study, 
including extent of compliance with GLP principles. Areas of non-compliance, particularly 
with biologicals, should be identified and their significance evaluated relative to the overall 
safety assessment [105]. 
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10.5 Good Manufacturing Practice (GMP) 
Any medicinal product intended to be administered to a human subject, be it for 
routine treatment or for clinical trial, should be manufactured and released in GMP-certified 
establishments under the supervision of a qualified person in accordance with the quality 
standards appropriate to their intended use and described in the clinical trial or MA dossier. 
GMP principles have been laid down for many years now, both in the US and Europe, and 
the general principles are fairly identical to the GLP rules. They mainly deal with the quality 
management system, personnel, premises and equipment, documentation, production, quality 
control as well as other activities surrounding the production system. Whereas some non-
clinical studies have been conducted, and accepted, without full compliance to GLP 
mandates, the GMP rules have to be applied for the production of any batches intended for 
humans. 
 
11. iPS Cells as An Alternative 
In some cases, the safety and/or efficacy of a new treatment can be first assessed in 
vitro using induced pluripotent stem cells (iPSCs). Since their discovery in 2007 [106], this 
ground breaking technology has been used to model diseases, interrogate drug response and 
toxicity, and create multiple cell types for therapeutic transplantation. To create iPSCs, 
somatic cells are first isolated from patient or animal tissues, including skin from punch 
biopsies, peripheral blood, lipoaspirate, cord blood, and amniotic fluid, among others. These 
cells are then induced to develop into a pluripotent state similar to embryonic stem cells 
(ESCs) through ectopic expression of pluripotency transgenes, bypassing the most 
controversial ethical concerns associated with ESCs. Induction of pluripotency gives these 
cells the innate ability to be propagated indefinitely, and to differentiate into therapeutic cell 
populations of all three germ layers, as demonstrated in cardiomyocytes (CMs), pancreatic 
beta-islet cells, hepatocytes, and neuronal cells [107-109]. 
The emergence of useful assays for the discovery and development of novel 
cardiovascular therapies depends on the ability to provide more efficient, predictive, and 
biologically relevant in vitro models to assess the potential on- and off-target toxicities of 
these new drugs. Once approved, approximately 4% of drugs are withdrawn from the market 
due to safety issues [110,111]. As discussed above, cardiac toxicity is the leading cause of 
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drug attrition during pharmaceutical development, and is a primary cause of drug withdrawal 
after market release, accounting for 42% of all drugs withdrawn due to safety concerns 
between 1994 and 2006 [112,113]. Under current phenotypic drug discovery approaches, a 
model is identified in which one or more key aspects of a disease process are recapitulated in 
vitro. Large compound libraries are then screened or new molecules synthesized to identify 
potential drugs that normalize function or correct/reverse the disease phenotype observed in 
vitro. Patient-specific iPSC-CMs make an ideal platform for drug discovery assays because 
of their capacity to recapitulate “disease in a dish” phenotypes [114]. 
The most extensively studied models are those of arrhythmic disorders caused by 
mutations in cardiac ion channels (“channelopathies”) [115]. Electrophysiological assessment 
using multi-electrode arrays (MEAs) and patch-clamp techniques enables identification of 
prolonged field/ action potentials (FP/ AP) in iPSC-CMs from patients carrying long-QT 
syndrome (LQTS) type 1 and type 2 mutations in potassium ion channels, which is associated 
with prolonged QT intervals on the patients’ electrocardiograms [116,117]. Another class of 
in vitro modeled cardiac disorders are the cardiomyopathies that are associated with 
deterioration in myocardial function and linked to heart failure and sudden cardiac death. One 
such disorder is dilated cardiomyopathy (DCM), which is characterized by ventricular 
dilation and systolic dysfunction. DCM iPSC-CMs carrying a cardiac troponin T (cTnT) 
mutation have demonstrated irregular sarcomeric organization, a scattered distribution pattern 
of Z bodies, reduction in contractile force, altered regulation of Ca
2+
 traffic, and decreased 
tolerance to β1-adrenergic challenge [118]. Similar to DCM, familial hypertrophic 
cardiomyopathy (HCM) is characterized by thickening primarily of the left ventricular wall 
and has been efficiently modeled using iPSC-CMs. Lan et al. [119] generated iPSCs carrying 
a thick myofilament myosin heavy chain 7 (MYH7) mutation, and demonstrated that iPSC-
CMs were significantly enlarged compared to controls and had increased myofibril content, 
contractile arrhythmias such as DADs, Ca
2+
 cycling perturbations, and intracellular Ca
2+
 
elevation. Adrenergic stimulation exacerbated Ca
2+
 transient irregularities and arrhythmias, 
mirroring the development of arrhythmias in HCM patients under sympathetic stimulation. 
These abnormalities were counteracted by the β-adrenergic blocker propranolol, or the L-type 
Ca
2+
 channel blocker verapamil, thus supporting the notion that Ca
2+
 cycling perturbations 
and intracellular Ca
2+
 elevation are central mechanisms for disease development at the 
cellular level. 
A separate study on the LEOPARD syndrome, a multi-organ condition in which 80% 
of patients present hypertrophic cardiomyopathy as the most life-threatening aspect, showed 
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that disease-specific iPSC-CMs had significantly increased median surface areas, sarcomeric 
disorganization, and nuclear factor of activated T cells (NFATC4) localization in the nucleus 
[120]. Patient-specific iPSC-CMs thus can provide not only a powerful platform for the 
identification of novel cardiovascular therapeutic targets and compounds, but may also help 
address the current lack of productivity in the pharmaceutical research and development 
process. By shifting attrition to the preclinical stage of heart failure drug development 
process, these cell lines not only could help aid in the early identification of lead drug 
candidates, but also accelerate the screening of cardiotoxic drugs and off-target effects of 
these pharmacological agents [121]. 
 
12. Ethics 
The principle of the three R’s (reduction, replacement, and refinement) should be 
applied throughout the animal experiments. The number of animals should be reduced as 
much as possible. A wide search of the literature will help avoid duplication of experiments. 
Power calculations should be used to determine the minimal number of animals needed for 
the experiments in order for the results to be meaningful. Tissue from the same animal can be 
used to assess many structural, functional, and metabolic parameters. To reduce variability, 
inbred strains of animals may be used, although results should always be validated in another 
strain or species. In vitro cell culture models, including iPSCs-derived cells, can be employed 
to replace the use of animals in certain conditions as described above. Procedures should be 
refined to minimize animal suffering, including the use of adequate anesthesia, analgesia, and 
post-operative care. Aseptic environments will reduce the risk of infection. Following 
procedures, all animals should be observed in an appropriate recovery cage or room, with 
continuous monitoring. These recommendations will help reduce mortality after procedures. 
Animals should be examined regularly for development of any adverse signs and symptoms 
indicating pain, distress or discomfort. Any animal with evidence of suffering excessive 




The usefulness and reproducibility of translational experiments strongly depend on 
how robustly they are reported [122]. Full recommendations on how to report animal 
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experiments have been provided in the ARRIVE guidelines [123]. Here we summarize some 
important aspects that should be taken into account. 
- Objectives. The study report should clearly indicate the initial hypothesis as well as the 
primary and secondary objectives. 
- Design and methodology. The experimental design of the study and the methodology used 
should be clearly described. Sample size, experimental groups, randomization, negative 
controls, experimental procedures, treatments, animal housing, and statistical methods should 
be elaborated sufficiently to enable confirmation of results. Ethical permissions should also 
be specified. 
- Construct validity threats. Limitations of the animal model used in the study and possible 
threats to the translation of results to humans should be clearly acknowledged.  
- Outcome and analysis. Results should include baseline characteristics and measurements for 
each animal group. All participating animals should be included in the report. If some of the 
animals are not included in the analysis, reasons for exclusion should be provided. Negative 
results should also be included and discussed in the final report. 
Useful checklists are provided in the ARRIVE guidelines and also for specific types of study 
designs, as assembled in the EQUATOR initiative [123,124]. 
 
14. Clinical Significance and Conclusions  
Despite advances in recent years, HF prognosis remains poor and the need to develop 
new therapies is urgent. Several interventions with therapeutic potential have been identified 
over the last two decades in animal models, mainly mice. However, translation of these 
results to the clinic has been minimal. Inappropriate or incomplete preclinical studies 
represent a major hurdle for the development of new therapies for HF. Animal models need 
to express the human patient characteristics more faithfully. The introduction of co-
morbidities and co-treatments in the experiments should be considered when establishing the 
model, and confounding variables should be controlled. Translational studies should address 
toxicity as well as efficacy, because many clinical trials fail due to lack of safety rather than 
lack of efficacy. A concerted, collective effort is needed to improve the usefulness of 
preclinical studies and boost the translation of results in animal experiments to humans. 
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Researchers should improve the experimental design, statistical analysis, and use rigorous 
methodology. Funding agencies should recognize the need for proper financing of 
translational experiments, which will likely be more expensive than exploratory projects 
focused on the generation of knowledge. Academic institutions should value the effort and 
time invested in a truly translational project. Regulatory agencies could demand stronger 
preclinical studies prior to entering clinical trials (the fact that the FDA expects positive 
inotropes and antiarrhythmic agents to be tested for arrhythmic activity in a cardiac disease 
model is a step in that direction). Similarly, scientific journals and other stakeholders could 
encourage the scientific community and the pharmaceutical industry to investigate species 
differences in adaptive and maladaptive responses to heart disease to increase the utility of 
animal studies in new cardiac drug discovery. These joint actions would help improve the 
quality of preclinical studies and reduce failure in subsequent clinical trials. 
 
15. Acknowledgements 
We are grateful to María Villalba Orero (CNIC, Madrid, Spain) for critical reading of the 
manuscript. 
 
16. Sources of Funding 
E.L.-P. was supported by grants from the European Union’s FP7 (CardioNeT-ITN-289600, 
CardioNext-ITN-608027), from the Spanish Ministry of Economy (SAF2012-31451) and 
from the Regional Government of Madrid (2010-BMD-2321 “Fibroteam”). The CNIC is 
supported by the Spanish Ministry of Economy and by the Pro-CNIC Foundation. J.A.H. was 
supported by grants from NIH (HL-120732; HL100401), AHA (14SFRN20740000), CPRIT 
(RP110486P3), and the Leducq Foundation (11CVD04). LB is supported by MINECO-SAF 
2013-42962R, from Instituto Carlos III (TERCEL-RD-12/00190026 and RIC12/00420024) 
and FP7-IMI-JU-SAFET -115003 by from the European Union. 
 
17. Disclaimer/Conflicts of Interest 
The authors have no conflict of interest. 
Page 33 of 43 
 
18. References 
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES et al 
(2014) Heart disease and stroke statistics—2014 Update: a report from the American Heart 
Association. Circulation 129:e28-e292. 
2. Krum H, Abraham WT (2009) Heart Failure. Lancet 373:941-955. 
3. Mcmurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi 
VC et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J 
Med 371:993-1004. 
4. Molloy GJ, O'carroll RE, Witham MD, Mcmurdo MET (2012) Interventions to enhance 
adherence to medications in patients with heart failure: a systematic review. Circ Heart Fail 
5:126-133. 
5. Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE (2009) Palliative care in the 
treatment of advanced heart failure. Circulation 120:2597-2606. 
6. Kandala J, Altman R, Park M, Singh J (2012) Clinical, laboratory, and pacing predictors of 
CRT response. J Cardiovasc Transl Res 5:196-212. 
7. Birks EJ, Tansley PD, Hardy J, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub 
MH (2006) Reversal of heart failure using a combination of left ventricular assist device 
(LVAD) and pharmacologic therapy. N Engl J Med 355:1873-1884. 
8. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends 
in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 
355:251-259. 
9. Zile M, Baicu C (2013) Biomarkers of diastolic dysfunction and myocardial fibrosis: 
application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 6:501-
515. 
10. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells 
DW, Ioannidis JPA et al (2014) How to increase value and reduce waste when research 
priorities are set. Lancet 383:156-165. 
11. Contopoulos-Ioannidis DG, Ntzani EE, Ioannidis JPA Translation of highly promising 
basic science research into clinical applications. Am J Med 114:477-484. 
12. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, 
Gibbons RJ et al (2011) New horizons in cardioprotection: recommendations from the 2010 
National Heart, Lung, and Blood Institute Workshop. Circulation 124:1172-1179. 
13. Sharma K, Kass DA (2014) Heart failure with preserved ejection fraction: mechanisms, 
clinical features, and therapies. Circ Res 115:79-96. 
14. Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG (2013) Threats 
to validity in the design and conduct of preclinical efficacy studies: a systematic review of 
guidelines for in vivo animal experiments. PLoS Med 10:e1001489. 
15. Investigators TCaSTC (1989) Preliminary report: effect of encainide and flecainide on 
mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New 
England Journal of Medicine 321:406-412. 
16. Breckenridge R (2010) Heart failure and mouse models. Dis Model Mech 3:138-143. 
17. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman 
HA, Kass DA et al (2012) Animal models of heart failure: A scientific statement from the 
American Heart Association. Circ Res 111:131-150. 
18. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J, 
Chien KR (1991) Segregation of atrial-specific and inducible expression of an atrial 
natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl 
Acad Sci U S A 88:8277-8281. 
Page 34 of 43 
 
19. Van Berlo JH, Maillet M, Molkentin JD (2013) Signaling effectors underlying pathologic 
growth and remodeling of the heart. J Clin Invest 123:37-45. 
20. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK et al 
(2010) A novel and efficient model of coronary artery ligation and myocardial infarction in 
the mouse. Circ Res 107:1445-1453. 
21. Vander Heide RS, Steenbergen C (2013) Cardioprotection and myocardial reperfusion: 
Pitfalls to clinical application. Circ Res 113:464-477. 
22. Rockman HA, Chien KR, Choi D-J, Iaccarino G, Hunter JJ, Ross J, Lefkowitz RJ, Koch 
WJ (1998) Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development 
of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 95:7000-7005. 
23. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch 
WJ (2009) Myocardial adeno-associated virus serotype-6-ARKct gene therapy improves 
cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 
119:89-98. 
24. Thai H, Guarraia D, Johnson N, Goldman S, Gaballa MA (2007) Valsartan therapy in 
heart failure after myocardial infarction: the role of endothelial dependent relaxation. J 
Cardiovasc Pharmacol 50:703-707 710.1097/FJC.1090b1013e318159378b. 
25. Defelice A, Harris A, Frering R, Horan P (1989) Beneficial hemodynamic effects of 
milrinone and enalapril in conscious rats with healed myocardial infarction. Eur J Pharmacol 
167:211-220. 
26. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ (1978) Angiotensin converting 
enzyme inhibition in patients with congestive heart failure. Circulation 58:770-776. 
27. Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on 
the infarcted left ventricle of the rat. Circ Res 57:84-95. 
28. Jeremy RW, Allman KC, Bautovitch G, Harris PJ (1989) Patterns of left ventricular 
dilation during the six months after myocardial infarction. J Am Coll Cardiol 13:304-310. 
29. Sweet CS, Ludden CT, Stabilito II, Emmert SE, Heyse JF (1988) Beneficial effects of 
milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J 
Pharmacol 147:29-37. 
30. The Solvd Investigators (1991) Effect of enalapril on survival in patients with reduced 
left ventricular ejection fractions and congestive heart failure. New England Journal of 
Medicine 325:293-302. 
31. Defelice A, Fein S, Daudiss K, Frering R, Horan P (1989) Beneficial hemodynamic 
effects of milrinone in conscious rabbits with chronic aortic regurgitation. J Cardiovasc 
Pharmacol 14:659-665. 
32. Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 
70:23-49. 
33. Vimercati C, Qanud K, Mitacchione G, Sosnowska D, Ungvari Z, Sarnari R, Mania D, 
Patel N et al (2014) Beneficial effects of acute inhibition of the oxidative pentose phosphate 
pathway in the failing heart. Am J Physiol Heart Circ Physiol 306:H709-H717. 
34. Bank A, Gage R, Burns K (2012) Right ventricular pacing, mechanical dyssynchrony, 
and heart failure. J Cardiovasc Transl Res 5:219-231. 
35. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, 
Leuchs B et al (2011) Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart 
failure in a preclinical large animal model. Sci Transl Med 3:92ra64. 
36. Tilemann L, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C, Kohlbrenner E, 
Fish KM et al (2013) SUMO-1 gene transfer improves cardiac function in a large-animal 
model of heart failure. Sci Transl Med 5:211ra159. 
Page 35 of 43 
 
37. Sabbah HN, Tocchetti CG, Wang M, Daya S, Gupta RC, Tunin RS, Mazhari R, Takimoto 
E et al (2013) Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. Circ 
Heart Fail 6:1250-1258. 
38. Liu Y, Dillon AR, Tillson M, Makarewich C, Nguyen V, Dell'italia L, Sabri AK, Rizzo V 
et al (2013) Volume overload induces differential spatiotemporal regulation of myocardial 
soluble guanylyl cyclase in eccentric hypertrophy and heart failure. J Mol Cell Cardiol 60:72-
83. 
39. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R et al 
(2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene 
transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51:1112-1119. 
40. Prunier F, Kawase Y, Gianni D, Scapin C, Danik SB, Ellinor PT, Hajjar RJ, Del Monte F 
(2008) Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase 
pump overexpression in a porcine model of ischemia reperfusion. Circulation 118:614-624. 
41. Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, Wang ZV, Morales C et al 
(2014) Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing 
cardiomyocyte autophagy. Circulation 129:1139-1151. 
42. Kou W, Nelson S, Lynch J, Montgomery D, Dicarlo L, Lucchesi B (1987) Effect of 
flecainide acetate on  prevention of electrical induction of ventricular tachycardia and 
occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction 
period:evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 9:359-365. 
43. Kaiser RA, Lyons JM, Duffy JY, Wagner CJ, Mclean KM, O'neill TP, Pearl JM, 
Molkentin JD (2005) Inhibition of p38 reduces myocardial infarction injury in the mouse but 
not pig after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 289:H2747-H2751. 
44. Van Den Borne SWM, Van De Schans VaM, Strzelecka AE, Vervoort-Peters HTM, 
Lijnen PM, Cleutjens JPM, Smits JFM, Daemen MJaP et al (2009) Mouse strain determines 
the outcome of wound healing after myocardial infarction. Cardiovasc Res 84:273-282. 
45. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S (2007) Cell isolation 
procedures matter: a comparison of different isolation protocols of bone marrow 
mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur 
Heart J 28:766-772. 
46. Hood L, Tian Q (2012) Systems approaches to biology and disease enable translational 
systems medicine. Genomics, proteomics & bioinformatics 10:181-185. 
47. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, Degeorge BR, Matkovich S 
et al (2008) G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after 
myocardial infarction prevents heart failure. Circ Res 103:413-422. 
48. Leinwand LA (2003) Sex is a potent modifier of the cardiovascular system. J Clin Invest 
112:302-307. 
49. Council NR. Guide for Care and Use of Laboratory Animals 8th Edition (2001)  
50. U.S. Food and Drug Administration. General Considerations for Animal Studies for 
Cardiovascular Devices (2010) 
http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm22
0760.htm. 
51. Peterson E, Augenstein J, Tanis D, Augenstein D (1981) Noise raises blood pressure 
without impairing auditory sensitivity. Science 211:1450-1452. 
52. Tucker D, Johnson A (1984) Influence of neonatal handling on blood pressure, locomotor 
activity, and preweanling heart rate in spontaneously hypertensive and Wistar Kyoto rats. 
17:587-600. 
53. Maury E, Ramsey KM, Bass J (2010) Circadian rhythms and metabolic syndrome: from 
experimental genetics to human disease. Circ Res 106:447-462. 
Page 36 of 43 
 
54. Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, Garvey ME, Frangogiannis NG, 
Michael LH, Chow C-W, Dyck JRB et al (2010) Short communication: ischemia/reperfusion 
tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. Circ 
Res 106:546-550. 
55. Shimizu T, Nakai K, Morimoto Y, Ishihara M, Oishi H, Kikuchi M, Arai H (2009) 
Simple Rabbit Model of Vulnerable Atherosclerotic Plaque. Neurol Med Chir 49:327-332. 
56. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum 
JL et al (2002) Lipid lowering reduces oxidative stress and endothelial cell activation in 
rabbit atheroma. Circulation 106:1390-1396. 
57. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, 
Hernández G et al (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal 
inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32:2057-2064. 
58. Largo R, Sánchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C, Granado R, 
Ortega L, Egido J et al (2008) Chronic arthritis aggravates vascular lesions in rabbits with 
atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. 
Arthritis Rheum 58:2723-2734. 
59. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human 
studies revisited. FASEB J 22:659-661. 
60. Behfar A, Latere J-P, Bartunek J, Homsy C, Daro D, Crespo-Diaz RJ, Stalboerger PG, 
Steenwinckel V et al (2013) Optimized delivery system achieves enhanced endomyocardial 
stem cell retention. Circ Cardiovasc Interv 6:710-718. 
61. Douglas PS, Decara JM, Devereux RB, Duckworth S, Gardin JM, Jaber WA, Morehead 
AJ, Oh JK et al (2009) Echocardiographic Imaging in Clinical Trials: American Society of 
Echocardiography Standards for Echocardiography Core Laboratories: Endorsed by the 
American College of Cardiology Foundation. J Am Soc Echocardiogr 22:755-765. 
62. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJS, Cleland JGF, Pennell DJ 
(2000) Comparison of left ventricular ejection fraction and volumes in heart failure by 
echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. 
Are they interchangeable? Eur Heart J 21:1387-1396. 
63. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, 
Roman MJ et al (2005) Recommendations for chamber quantification: a report from the 
American Society of Echocardiography's Guidelines and Standards Committee and the 
Chamber Quantification Writing Group, developed in conjunction with the European 
Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc 
Echocardiogr 18:1440-1463. 
64. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE (2012) Performance of 
3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: 
a systematic review and meta-analysis. J Am Coll Cardiol 59:1799-1808. 
65. Tee M, Noble JA, Bluemke DA (2013) Imaging techniques for cardiac strain and 
deformation: comparison of echocardiography, cardiac magnetic resonance and cardiac 
computed tomography. Expert Rev Cardiovasc Ther 11:221-231. 
66. Gorcsan Iii J, Tanaka H (2011) Echocardiographic assessment of myocardial strain. J Am 
Coll Cardiol 58:1401-1413. 
67. Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH (2014) Use of 
myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in 
patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 
63:2751-2768. 
68. Chemaly ER, Chaanine AH, Sakata S, Hajjar RJ (2012) Stroke volume-to-wall stress 
ratio as a load-adjusted and stiffness-adjusted indicator of ventricular systolic performance in 
chronic loading. J Appl Physiol (1985) 113:1267-1284. 
Page 37 of 43 
 
69. Ishikawa K, Chemaly ER, Tilemann L, Fish K, Ladage D, Aguero J, Vahl T, Santos-
Gallego C et al (2012) Assessing left ventricular systolic dysfunction after myocardial 
infarction: are ejection fraction and dP/dtmax complementary or redundant? Am J Physiol 
Heart Circ Physiol 302:H1423-H1428. 
70. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, 
Flachskampf FA et al (2009) Recommendations for the evaluation of left ventricular diastolic 
function by echocardiography. J Am Soc Echocardiogr 22:107-133. 
71. Enriquez-Sarano M, Akins CW, Vahanian A Mitral regurgitation. Lancet 373:1382-1394. 
72. Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, 
Fuster V et al (2007) Early metoprolol administration before coronary reperfusion results in 
increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac 
magnetic resonance. Circulation 115:2909-2916. 
73. Neilan TG, Coelho-Filho OR, Shah RV, Abbasi SA, Heydari B, Watanabe E, Chen Y, 
Mandry D et al (2013) Myocardial extracellular volume fraction from T1 measurements in 
healthy volunteers and mice: Relationship to aging and cardiac dimensions. JACC 
Cardiovasc Imaging 6:672-683. 
74. Panse K, Felkin L, López-Olañeta M, Gómez-Salinero J, Villalba M, Muñoz L, 
Nakamura K, Shimano M et al (2012) Follistatin-like 3 mediates paracrine fibroblast 
activation by cardiomyocytes. J Cardiovasc Transl Res 5:814-826. 
75. Felkin LE, Narita T, Germack R, Shintani Y, Takahashi K, Sarathchandra P, López-
Olañeta MM, Gómez-Salinero JM et al (2011) Calcineurin splicing variant CnAβ1 improves 
cardiac function after myocardial infarction without inducing hypertrophy. Circulation 
123:2838-2847. 
76. López-Olañeta MM, Villalba M, Gómez-Salinero JM, Jiménez-Borreguero LJ, 
Breckenridge R, Ortiz-Sánchez P, García-Pavía P, Ibáñez B et al (2014) Induction of the 
calcineurin variant CnAβ1 after myocardial infarction reduces post-infarction ventricular 
remodelling by promoting infarct vascularization. Cardiovasc Res 102:396-406. 
77. Felkin L, Lara-Pezzi E, Hall J, Birks E, Barton P (2011) Reverse remodelling and 
recovery from heart failure are associated with complex patterns of gene expression. J 
Cardiovasc Transl Res 4:321-331. 
78. Choudhary R, Iqbal N, Khusro F, Higginbotham E, Green E, Maisel A (2013) Heart 
failure biomarkers. J Cardiovasc Transl Res 6:471-484. 
79. Vilahur G, Cubedo J, Casani L, Padro T, Sabate-Tenas M, Badimon JJ, Badimon L 
(2013) Reperfusion-triggered stress protein response in the myocardium is blocked by post-
conditioning. Systems biology pathway analysis highlights the key role of the canonical aryl-
hydrocarbon receptor pathway. Eur Heart J 34:2082-2093. 
80. Barth A, Chakir K, Kass D, Tomaselli G (2012) Transcriptome, proteome, and 
metabolome in dyssynchronous heart failure and CRT. J Cardiovasc Transl Res 5:180-187. 
81. Bravo P, Bengel F (2011) The role of cardiac PET in translating basic science into the 
clinical arena. J Cardiovasc Transl Res 4:425-436. 
82. Schroeder MA, Lau AZ, Chen AP, Gu Y, Nagendran J, Barry J, Hu X, Dyck JRB et al 
(2013) Hyperpolarized 13C magnetic resonance reveals early- and late-onset changes to in 
vivo pyruvate metabolism in the failing heart. Eur J Heart Fail 15:130-140. 
83. Defelice A, Frering R, Horan P (1989) Time course of hemodynamic changes in rats with 
healed severe myocardial infarction. Am J Physiol 257:H289-H296. 
84. Ioannidis JPA (2005) Why most published research findings are false. PLoS Med 2:e124. 
85. Ioannidis JPA (2008) Why most discovered true associations are inflated. Epidemiology 
19:640-648 610.1097/EDE.1090b1013e31818131e31818137. 
86. Nishida K, Michael G, Dobrev D, Nattel S (2010) Animal models for atrial fibrillation: 
clinical insights and scientific opportunities. Europace 12:160-172. 
Page 38 of 43 
 
87. Morgan SJ, Elangbam CS, Berens S, Janovitz E, Vitsky A, Zabka T, Conour L (2013) 
Use of Animal Models of Human Disease for Nonclinical Safety Assessment of Novel 
Pharmaceuticals. Toxicol Pathol 41:508-518. 
88. Schreiner K, Voss F, Senges J, Becker R, Kraft P, Bauer A, Kelemen K, Kuebler W et al 
(2004) Tridimensional activation patterns of acquired torsade-de-pointes-tachycardias in dogs 
with chronic AV-block. Basic Res Cardiol 99:288-298. 
89. Vrána M, Fejfar Z, Netu'sil M, Blazek Z, Trcka V (1978) Stimulation threshold studies 
and the effect of antiarrhythmic drugs. Basic Res Cardiol 73:618-676. 
90. Fazekas T, Scherlag B, Mabo P, Patterson E, Lazzara R (1994) Facilitation of reentry by 
lidocaine in canine myocardial infarction. Acta Physiol Hung 82:201-213. 
91. Táborský M, Heinc P, Doupal V (2010) Antiarrhythmic agents vs implantable 
cardioverter-defibrillators in the prevention of sudden cardiac death: finally resolved issue? 
Kardiol Rev Int Med 12(suppl):26-31. 
92. Zbinden G (1993) The Concept of Multispecies Testing in Industrial Toxicology. Regul 
Toxicol Pharmacol 17:85-94. 
93. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, 
Mcgrew F et al (1998) A Dose-Dependent Increase in Mortality with Vesnarinone among 
Patients with Severe Heart Failure. N Engl J Med 339:1810-1816. 
94. Boulaksil M, Jungschleger JG, Antoons G, Houtman MJC, De Boer TP, Wilders R, 
Beekman JD, Maessen JG et al (2011) Drug-induced torsade de pointes arrhythmias in the 
chronic AV block dog are perpetuated by focal activity. Circ Arrhythm Electrophysiol 4:566-
576. 
95. Kozhevnikov DO, Yamamoto K, Robotis D, Restivo M, El-Sherif N (2002) 
Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to 
acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery 
pattern. Circulation 105:1128-1134. 
96. Hernandez R, Mann DE, Breckinridge S, Williams GR, Reiter MJ (1989) Effects of 
flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 14:777-781. 
97. Nicholson C, Jackman S, Wilke R (1989) Ability of denbufylline to inhibit cyclic 
nucleotide phosphodiesterasand its affinity for adenosine receptor and adenosine reuptake 
site. Br J Pharmacol 97:889-900. 
98. Desjardins S, Cauchy MJ (1995) Comparative cardiac effects of milrinone and sodium 
nitroprusside in rats. Drug Chem Toxicol 18:43-59. 
99. Alousi A, Canter J, Montenaro M (1983) Cardiotonic activity of milrinone, a new potent 
cardiac bipyridine, on the normal and failing heart of experimental animals. J Clin Pharmacol 
5:792-803. 
100. Lynch J, Uprichard A, Frye J, Driscoll E, Kitzen J, Lucchesi B (1989) Effects of the 
positive inotropic agents milrinone and pimobendan on the development of lethal ischemic 
arrhythmias in conscious dogs with recent myocardial infarction. J Cardiovasc Pharmacol 
14:585-597. 
101. U.S. Food and Drug Administration. Code of Federal Regulations. Good Laboratory 
Practice for nonclinical laboratory studies (2013) 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58&show
FR=1. 
102. Commission E. Directive 2001/83/EC of the European Parliament and of the Council on 
the Community code relating to medicinal products for human use (2001) 
http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_cons/dir2001_83_cons_20081230_en.pdf. 
Page 39 of 43 
 
103. Abbasalizadeh S, Baharvand H (2013) Technological progress and challenges towards 
cGMP manufacturing of human pluripotent stem cells based therapeutic products for 
allogeneic and autologous cell therapies. Biotechnol Adv 31:1600-1623. 
104. European Commission. Directive 2001/83 and its annex I on the Community code 
relating to medicinal products for human use (2001) 
http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_cons/dir2001_83_cons_20081230_en.pdf. 
105. International Conference on Harmonisation. Harmonized tripartite guideline on 
preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1) (1997) 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step
4/S6_R1_Guideline.pdf. 
106. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S 
(2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. 
Cell 131:861-872. 
107. Burridge PW, Keller G, Gold JD, Wu JC (2012) Production of de novo cardiomyocytes: 
human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10:16-
28. 
108. Matsa E, Sallam K, Wu JC (2014) Cardiac stem cell biology: glimpse of the past, 
present, and future. Circ Res 114:21-27. 
109. Montserrat N, Bahima E, Batlle L, Häfner S, Rodrigues A, González F, Belmonte J 
(2011) Generation of pig iPS cells: a model for cell therapy. J Cardiovasc Transl Res 4:121-
130. 
110. Mordwinkin NM, Lee AS, Wu JC (2013) Patient-specific stem cells and cardiovascular 
drug discovery. JAMA : the journal of the American Medical Association 310:2039-2040. 
111. Mordwinkin N, Burridge P, Wu J (2013) A review of human pluripotent stem cell-
derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and 
publication standards. J Cardiovasc Transl Res 6:22-30. 
112. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht 
AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand 
challenge. Nat Rev Drug Discov 9:203-214. 
113. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in 
pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:191-200. 
114. Matsa E, Denning C (2012) In vitro uses of human pluripotent stem cell-derived 
cardiomyocytes. J Cardiovasc Transl Res 5:581-592. 
115. Yazawa M, Dolmetsch R (2013) Modeling Timothy syndrome with iPS cells. J 
Cardiovasc Transl Res 6:1-9. 
116. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A et 
al (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N 
Engl J Med 363:1397-1409. 
117. Wang Y, Liang P, Lan F, Wu H, Lisowski L, Gu M, Hu S, Kay MA et al (2014) 
Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT 
phenotype for drug testing. J Am Coll Cardiol. 
118. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S et al 
(2012) Patient-specific induced pluripotent stem cells as a model for familial dilated 
cardiomyopathy. Sci Transl Med 4:130ra147. 
119. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M et al 
(2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy 
pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12:101-113. 
Page 40 of 43 
 
120. Carvajal-Vergara X, Sevilla A, D'souza SL, Ang YS, Schaniel C, Lee DF, Yang L, 
Kaplan AD et al (2010) Patient-specific induced pluripotent stem-cell-derived models of 
LEOPARD syndrome. Nature 465:808-812. 
121. Matsa E, Burridge PW, Wu JC (2014) Human stem cells for modeling heart disease and 
for drug discovery. Sci Transl Med 6:239ps236. 
122. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D 
et al Reducing waste from incomplete or unusable reports of biomedical research. Lancet 
383:267-276. 
123. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving 
bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS 
Biol 8:e1000412. 
124. Simera I, Moher D, Hoey J, Schulz KF, Altman DG (2010) A catalogue of reporting 
guidelines for health research. Eur J Clin Invest 40:35-53. 
  
  




Table 1. General aims of translational experiments 
1. Efficacy. Assess pharmacodynamic or beneficial effects of a treatment 
2. Safety. Investigate potential toxicity of the treatment 
3. Validity. Choose a heart failure model that mimics the human condition as closely as 
possible, including co-morbidities, routes of therapy administration and analytical methods 
4. Standardization. Use standardized protocols that will allow results to be compared and 
reproduced by other researchers 
5. Type of preclinical study. Consider that proof of concept studies to establish efficacy are 
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Table 2. General recommendations for animal models and experimental design in 
preclinical heart failure studies  
 
1. Animal model. The chosen model should recapitulate human HF as much as possible. 
Small animals have advantages for initial POC studies, but large animals are better suited for 
preclinical studies prior to clinical trials in humans. 
2. Comorbidities. HF patients usually present comorbidities (e.g. CAD, hypertension) that 
may influence the outcome of the treatment. Consider including comorbidities in the 
experimental design. 
3. Species and Strains. Results should be validated in different strains and species. 
4. Induction of disease. The way human disease is induced in an animal model may alter the 
effect of the treatment and should be carefully considered. 
5. More than one model. Results should be validated in a second HF animal model. 
6. Reproducibility. Results should be reproduced by independent laboratories to avoid 
confounding effects of environmental factors, methodology, reagents, infrastructure, etc. 
7. Standard of care. It is advisable to compare new treatments to SOC, starting with studies 
in small animals. 
8. Age and Sex. HF is mainly associated with the elderly. Researchers should consider 
carrying out translational studies in older animals of both sexes. 
9. Negative controls. These should be carefully chosen and may involve sham surgery 
procedures and/or administration of control substances, viral vectors or cells, among others. 
10. Randomization and blinding. Rigorous randomization and blinding of the investigators 
carrying out the procedures are essential to reduce biases and are strongly recommended. 
11. Timing and dose response should try to anticipate the eventual extension of successful 
interventions to human clinical trials and human use. 
12. Inclusion/Exclusion criteria should be clearly defined a priori based on pathophysiology 
considerations, previous studies, or other evidence. 
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Table 3. Summary of endpoints and analyses to be carried out in preclinical HF models. 
Endpoints     Methodology 
Cardiac function    Echocardiography, MRI 
Myocardial remodeling Echocardiography, MRI, left ventricular 
manometer, Swan-Ganz catheter (Pressure-
Volume relationship) 
Cardiac metabolism PET, MRS, biochemistry 
Tissue remodeling, fibrosis, inflammation MRI, histology, immunohistochemistry, qRT-
PCR, Western blot, ELISA 
Confirmation of treatment delivery qPCR, qRT-PCR, Western blot, 
immunohistochemistry 
Secondary effects Histology, ELISA, qPCR, qRT-PCR, 
immunohistochemistry 
Survival Visual score, follow welfare protocols 
 
MRI, magnetic resonance imaging; PET, positron emission tomography; MRS, magnetic 
resonance spectroscopy; qRT-PCR, quantitative reverse-transcribed polymerase chain 
reaction; qPCR, quantitative polymerase chain reaction; ELISA, enzyme-linked 
immunosorbent assay. 
 
